Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

748.19 -7.20 (-0.95%)
Official Closing Price Updated: 4:10 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novo Nordisk's Weight-Loss Wonders Drive Q2 Growth Amidst Shifting Sands of Competition
Novo Nordisk (NYSE: NVO) has once again demonstrated formidable strength in its obesity care segment, with powerhouse drugs Wegovy and Ozempic propelling the company to a robust Q2 2025 performance.... 
Via MarketMinute
Topics Economy Intellectual Property
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
Novo Nordisk Faces Headwinds: Competitive Pressures and Compounded Drugs Force Lowered Outlook
Copenhagen, Denmark – Novo Nordisk (NASDAQ: NVO), the pharmaceutical powerhouse synonymous with diabetes and obesity care, has significantly pared back its full-year sales and profit projections for... 
Via MarketMinute
Topics Economy Intellectual Property Law Enforcement
Eli Lilly, Novo Nordisk Preparing To Introduce Obesity Pills Next Year In The US: Report
Via Stocktwits
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
Via Stocktwits
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
Why Novo Nordisk Stock Popped Today
A price cut could help get Novo Nordisk stock back in the race against Eli Lilly. 
Via The Motley Fool
1 Stock That Should Be in Every Investor's Portfolio
Eli Lilly has seen weakness in its stock price year to date. I think it's a short-term problem. 
Via The Motley Fool
3 Monster Stocks to Hold for the Next 5 Years
They could deliver market-beating returns beyond 2030. 
Via The Motley Fool
Topics Artificial Intelligence
Eli Lilly, Novo Nordisk’s Weight-Loss Drugs Deemed Cost-Effective By Pricing Watchdog: BofA Deems Decision A ‘Win’
Via Stocktwits
2 Beaten-Down Stocks to Buy and Hold Forever
Their prospects look intact despite some recent roadblocks. 
Via The Motley Fool
Topics Artificial Intelligence World Trade
This Vanguard ETF Makes It Easy to Invest in the "Magnificent Seven"
The "Magnificent Seven" stocks have done incredibly well over the past five years, with six of them more than doubling in value during that time frame. 
Via The Motley Fool
Topics ETFs
3 No-Brainer Dividend Stocks to Buy in September
The attraction of these dividend stocks isn't limited to their dividends. 
Via The Motley Fool
Topics Intellectual Property
The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment
The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is... 
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
Eli Lilly Loses Appeal Over Medicaid Drug Pricing Fraud Case
A U.S. appeals court upheld a $183.7 million judgment against Eli Lilly in a whistleblower case, finding the company misreported drug prices and shorted Medicaid rebates. 
Via Benzinga
Topics Fraud Whistleblower
Here's How Much $100 Invested In Eli Lilly 15 Years Ago Would Be Worth Today
 
Via Benzinga
This Under-the-Radar Healthcare Stock Could Soar in 2026
We should know a lot more by year-end. 
Via The Motley Fool
1 Super Stock Down More Than 20% to Buy Hand Over Fist, According to Wall Street
The positives for this big drugmaker appear to outweigh the negatives. 
Via The Motley Fool
Topics Earnings Government World Trade
Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio
The Vanguard Growth ETF provides concentrated exposure to the market's most innovative giants and has a proven history of strong, long-term returns. 
Via MarketBeat
Topics Artificial Intelligence ETFs Economy
Prediction: After a Tough Summer for Healthcare Stocks, These 2 Companies Can Make a Comeback
One of them is already a leader in the market for weight management drugs, and the other could join this field. 
Via The Motley Fool
Topics ETFs
Why Eli Lilly's Stock Could Be Gearing Up for a Big Rally
Lilly could launch its GLP-1 pill by this time next year. 
Via The Motley Fool
2 Undervalued Healthcare Stocks to Buy in 2025 and Hold for Decades
A decade from now, you could regret ignoring these no-brainer stock picks. 
Via The Motley Fool
Topics Intellectual Property
2 Monster Stocks to Hold for the Next 5 Years
These companies each are leaders in today's highest-growth industries. 
Via The Motley Fool
Topics Artificial Intelligence
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. 
Via Benzinga
The Smartest Vanguard ETF to Buy With $1,000 Right Now
A fund like the Vanguard Dividend Appreciation ETF can help hedge against a potential market pullback. 
Via The Motley Fool
Topics ETFs
Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'
Novo Nordisk (NYSE: NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant... 
Via Benzinga
Defiance Has A New ETF For High-Stakes Pharma Traders
Defiance's LLYZ ETF offers 2X inverse daily exposure to Eli Lilly, giving traders a high-risk, short-term way to bet on stock pullbacks without shorting. 
Via Benzinga
Topics ETFs
Eli Lilly Meshes AI With Drug Research, Touts $1B Worth Of Research Data
Eli Lilly's new TuneLab platform gives biotech firms AI-powered drug discovery tools using $1 billion of proprietary research. 
Via Benzinga
Topics Artificial Intelligence
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.